CD207 CAR-T cells

Phase 1Cell therapy

BBeijing Friendship Hospital

CD207 CAR-T cells is one of 31 biologic programs targeting Langerhans Cell Histiocytosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Langerhans Cell HistiocytosisActive, not recruiting

Langerhans Cell HistiocytosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Langerhans Cell Histiocytosis

#DrugCompanyPhaseTrials

Thalomid

Tabloid

Cytoxan

BBaxter Healthcare Corporation

Approved

—4

Decadron

AAspen Global Incorporated

Cytosar

2 6

Purinethol

SStason

Phase 3

2 7

Indocin

LLife Extension Foundation Inc.

Phase 3

1 8

Immunoglobulin

Sanofi

Phase 3

1 9

Trexall

Alnylam Pharmaceuticals

Phase 2

3 10

Mekinist

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Langerhans Cell Histiocytosis1 trial

Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis

Unknown status·—·Phase 1·NCT05477446·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD207 CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD207 CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD207 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Friendship Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: BBeijing Friendship Hospital

CD207 CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Langerhans Cell Histiocytosis1 trial

References

Drug Info

Quick Facts

Related News